Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.33 |
| ▸ | CTSS | P25774 | 9/20 | 0.33 |
| ▸ | CTSL | P07711 | 3/20 | 0.33 |
| ▸ | CTSB | P07858 | 5/20 | 0.32 |
| ▸ | OGG1 | O15527 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.31 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR7 | P34969 | 1/20 | 0.30 |
| ▸ | HTR6 | P50406 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6836674 | 0.89 | CTSK (0.35) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6430414 | 0.85 | CTSL (0.33) | CTSKCTSSCTSLCTSBDRD2 | |
| SCHEMBL6432598 | 0.84 | CTSK (0.35) | CTSKCTSSCTSB | |
| SCHEMBL6832864 | 0.83 | CTSS (0.34) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6356473 | 0.81 | CTSL (0.33) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6356480 | 0.81 | CTSL (0.33) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6836028 | 0.79 | KMT2A (0.41) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6346011 | 0.78 | CTSL (0.34) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6346009 | 0.78 | CTSL (0.34) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6346016 | 0.78 | CTSL (0.34) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006078-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | CTSK 2/4885CTSS 1/4885CTSL 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.